A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs - Wikidata - awgldk - TriplyDB

A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

http://www.wikidata.org/entity/Q28264524

about

Toxic epidermal necrolysis and Stevens-Johnson syndrome 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing The genetics of hyperuricaemia and gout Clinical use of pharmacogenomic tests in 2009 Impact of New Genomic Technologies on Understanding Adverse Drug Reactions Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy.New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity Evolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response.Idiosyncratic adverse drug reactions: current concepts Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis Pharmacogenomics of adverse drug reactions Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.Review of Toxic Epidermal Necrolysis Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical Implementation The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity ABC transporters and the proteasome complex are implicated in susceptibility to Stevens-Johnson syndrome and toxic epidermal necrolysis across multiple drugs Genome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Europe Human leucocyte antigen-adverse drug reaction associations: from a perspective of ethnicity.Pharmacogenomics of off-target adverse drug reactions.Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry.Genotyping for severe drug hypersensitivity.The genetics of gout: towards personalised medicine?Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): An Interplay among Drugs, Viruses, and Immune System.Trans-ethnic study confirmed independent associations of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe ocular surface complications.Pharmacogenetics of drug hypersensitivity.HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients.The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis.Allopurinol pharmacogenetics: assessment of potential clinical usefulness.In silico analysis of HLA associations with drug-induced liver injury: use of a HLA-genotyped DNA archive from healthy volunteers Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.Polymorphism in glutamate cysteine ligase catalytic subunit (GCLC) is associated with sulfamethoxazole-induced hypersensitivity in HIV/AIDS patients Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions.Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach.Human leukocyte antigen typing using a knowledge base coupled with a high-throughput oligonucleotide probe array analysis.Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese.Drug hypersensitivity: pharmacogenetics and clinical syndromes.Copy number variants in pharmacogenetic genes.PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.

P2860

Q21202877-F619AB30-103A-4D78-99E3-A3E9687C2640 Q24612292-6F266D59-BA59-4F74-9C57-82B0047CE547 Q24626941-78AF2375-2E59-48BA-B8C3-3AC0976A05BC Q24629964-E6D2DDF8-57AB-4806-981D-FC865AD0E411 Q24657536-E8E3FD37-0AE4-49CE-A7DD-1F8C958456D1 Q26787099-A1962832-5000-4FC5-A763-B536E818EDC4 Q26800964-721D3203-6471-4BF8-A187-E829323BA128 Q26800976-1DD8D464-22B1-48F3-80B2-221EB63A3D62 Q26800980-2956C0C1-4E9C-43A1-8E87-A7FCDDC05E35 Q26824391-16F21CA9-B905-4A73-9C71-A4F67688CE0E Q26853305-C253A857-203C-4F58-BC6B-8E10F6F1B4B0 Q27015820-CC272A35-A8F5-4450-A3CB-41C6CEABD5D9 Q27692095-5C499530-E7FB-4D4B-9BD1-BB65DDCE9816 Q28074097-C193E094-092A-4570-B5CD-832847F7B58A Q28076600-5BE04FC3-95BB-4C98-B94E-9B56EF6DA9F7 Q28080256-00826459-05E9-4269-B761-EBA04A03362A Q28545799-22C5A9BF-2864-48CD-82A7-8CF664EAA6F4 Q28943413-12149D2F-048D-402A-8074-11BE876EE873 Q30238992-7E596D5C-B7DD-44B0-B7B9-595D0B4D59C2 Q30400366-2974AAE2-693D-4B3E-9E7E-62629D25EBD8 Q31033074-DE040838-687F-4902-BFBA-D2F58DD06898 Q33582530-67F7FC90-EEA6-42CE-8919-64E950D17172 Q33750522-C5CFAF90-0CFB-4B64-8B57-7432B7C5DCB7 Q33838853-3F4A5660-DA91-4551-9CCE-6C9738C689D6 Q34013280-872C51B8-AFA9-42F2-9841-776E5C5F0A14 Q34118186-0F4C0F41-E6B1-49EB-B555-3B33F7C0B1C1 Q34172669-57631567-EDE7-4695-9575-8679BACD6209 Q34215820-5621FFE5-B1C6-4460-9889-B7DE81D6D683 Q34225850-3B9E73EE-24B4-4196-B345-10401F4AA609 Q34236067-06257820-C23E-4A1F-BEBD-D1C239A2F3F4 Q34316771-FE3B7BC6-3B7F-492B-975C-F1A131F5530F Q34345953-31A5E1B0-0EC6-47A8-A20D-D92B440F0A8A Q34348246-33BA29EB-19F0-4F6F-B049-DBDCF61060E9 Q34408357-AA802263-0E9B-4AB7-96E2-E29410611A3B Q34557668-B388F006-3F62-440D-974B-869DD1269ACF Q34579653-EC27B214-1BF4-40F8-BAF1-16CD19211BAF Q34617803-0E3E4217-15A4-4E8A-BDC1-6DC730532899 Q34701492-B9A752D3-51EC-478D-A93D-9ACC3F875397 Q34975631-D5CC676D-A4F2-4729-A9FE-E017EC509903 Q35168561-AD19BA16-84CF-407A-B052-701CF327611B

P2860

A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

http://www.wikidata.org/entity/Q28264524

description

2008 nî lūn-bûn

@nan

2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

A European study of HLA-B in S ...... elated to five high-risk drugs

@ast

A European study of HLA-B in S ...... elated to five high-risk drugs

@en

A European study of HLA-B in S ...... elated to five high-risk drugs

@nl

type

label

A European study of HLA-B in S ...... elated to five high-risk drugs

@ast

A European study of HLA-B in S ...... elated to five high-risk drugs

@en

A European study of HLA-B in S ...... elated to five high-risk drugs

@nl

prefLabel

A European study of HLA-B in S ...... elated to five high-risk drugs

@ast

A European study of HLA-B in S ...... elated to five high-risk drugs

@en

A European study of HLA-B in S ...... elated to five high-risk drugs

@nl

P1433

Q28264524-6F9702FE-0CFC-4E7C-B1C3-AD161935CFF3

P1476

Q28264524-03F45B1D-49AF-4D65-A01A-2699F88CFDCD

P2093

Q28264524-20E14F55-59BF-4EC4-877F-D188BF955ED6

Q28264524-504226A5-F7FA-47D6-95F8-C695DE214E40

Q28264524-5A7A464B-2A85-4B00-86A5-39281AC61140

Q28264524-686FDBAD-DB4B-43EC-95FC-05E60CF4AB9B

Q28264524-75F16FBA-CFAF-4D73-B529-3CFFF8DC051F

Q28264524-A000B704-E2B8-4502-A650-83FCE401C6D1

Q28264524-E09D8A08-99E5-4B89-9DFF-4FF6FFBC638E

Q28264524-E89BEAFD-43EE-4C5E-982D-968740056354

Q28264524-F4E1EAA6-D6AE-4697-9B99-5CAA89193067

Q28264524-FFC66637-2596-4182-AE9A-DDA6E352CCC9

P304

Q28264524-3413C372-D51D-4452-8EC9-8A1A6C89D197

P31

Q28264524-C8462381-4F71-4392-92A5-768D18D6D14C

P3181

Q28264524-6829BF8F-25FB-4EF7-8085-5B622DEA6779

P356

Q28264524-1D47C163-3B8B-4E61-BDDB-967E9E85E354

P407

Q28264524-30EA7070-9B3D-4B10-A7E0-1540FBE0CFF7

P433

Q28264524-ADC68D25-8322-4B5B-9502-D11B679DC9ED

P478

Q28264524-DFFF9060-2602-4671-9C7F-BD4153FAE4B7

P50

Q28264524-315D6C3D-423B-47BF-8584-0E7E495059FA

Q28264524-5FE8455A-F407-4C58-A678-F91A14F4F8B7

Q28264524-82C5AEBE-5B6E-4AB7-925E-C5192D0CC3B9

Q28264524-89715089-F0D7-4678-8A49-10EDD41E34F8

P577

Q28264524-CF2193DE-3D28-4738-8CC8-C7AF494EB3A2

P698

Q28264524-98C18560-291E-4B66-95FE-CF8E253A3034

P3181

P356

FPC.0B013E3282F3EF9C

P1433

Pharmacogenetics and Genomics

P1476

A European study of HLA-B in S ...... elated to five high-risk drugs

@en

P2093

Alexis Sidoroff

http://www.w3.org/2001/XMLSchema#string

Claudia de Toma

http://www.w3.org/2001/XMLSchema#string

Jan-Nico Bouwes-Bavinck

http://www.w3.org/2001/XMLSchema#string

Jean-Claude Roujeau

http://www.w3.org/2001/XMLSchema#string

Laure Thomas

http://www.w3.org/2001/XMLSchema#string

Maja Mockenhaupt

http://www.w3.org/2001/XMLSchema#string

Martin Schumacher

http://www.w3.org/2001/XMLSchema#string

Neil Ledger

http://www.w3.org/2001/XMLSchema#string

Nicolas Borot

http://www.w3.org/2001/XMLSchema#string

Sima Halevy

http://www.w3.org/2001/XMLSchema#string

P304

99-107

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3018652

http://www.w3.org/2001/XMLSchema#string

P356

10.1097/FPC.0B013E3282F3EF9C

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Alain Hovnanian

P577

2008-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18192896

http://www.w3.org/2001/XMLSchema#string